Review examines macrophages’ dual role and treatment challenges in exocrine gland fibrosis in Sjögren’s syndrome

Background
In Sjögren’s syndrome, macrophages contribute to inflammation and tissue repair, but in a chronically inflamed environment they may also promote fibrosis. A review published in the international journal Frontiers in Immunology synthesizes existing literature to explain these changing roles and outlines challenges that remain before macrophages can be used as therapeutic targets. The central issue is distinguishing their inflammation-limiting functions from their fibrosis-promoting functions.
Sjögren’s syndrome (SS) is a chronic systemic autoimmune disease characterized by damage to exocrine glands, including the salivary and lacrimal glands; dry mouth and dry eyes are its hallmark symptoms. Persistent inflammation and fibrosis damage gland structure and secretory function. The review distinguishes local symptom management from systemic immunomodulatory treatment, while noting that no effective treatment reverses established gland fibrosis. This limitation has drawn attention to macrophages, which link inflammation with tissue damage.
Key findings
The authors synthesize the literature into a framework in which inflammatory M1 macrophages predominate early, interactions between M1 and M2 macrophages sustain chronic inflammation in the middle stage, and abnormal fibrosis-promoting M2 functions become more prominent later. This is an account of existing research, not the result of a new clinical trial. It should not be treated as a rule that every patient progresses through the same sequence.
Changes in macrophage functional state in response to surrounding signals are called polarization. Gland tissue can also contain phenotypes with overlapping inflammatory and repair functions, so the M1/M2 dichotomy alone cannot fully describe cellular diversity. M2 macrophages do not have a single role either. Appropriate activation can limit excessive inflammation and support tissue repair, but persistent fibrosis-promoting activity in a chronic environment may worsen damage. This is why an increase in M2 macrophages alone is difficult to interpret as evidence of recovery when evaluating therapeutic candidates.
The fibrosis mechanisms discussed in the review include transforming growth factor beta 1 (TGF-β1) and YKL-40. These factors, secreted by abnormally activated M2 macrophages, are described as promoting fibroblast activation and the accumulation of collagen and other extracellular matrix components. The review also discusses feedback in which activated fibroblasts further reinforce the fibrosis-promoting state of macrophages. However, evidence is limited for establishing causality and the progression of these changes over time in human gland tissue.
Factors that regulate macrophage states include signaling between immune cells, intracellular signaling pathways, gene-expression regulation by non-coding RNAs, and changes in energy metabolism. The review also describes the potential of some traditional Chinese medicine formulas and compounds to regulate polarization, but the relevant research is largely limited to cell and animal studies. Given the lack of sufficient validation in large clinical cohorts or randomized controlled trials, treatment efficacy and safety in patients cannot be considered established.
Implications and outlook
The direction proposed by the review is to distinguish among suppressing inflammation, supporting repair, and blocking fibrosis according to disease stage and tissue state. To translate this into treatment, researchers first need to determine which macrophage subtypes should be modulated, and when. Much of the human evidence is based on correlation analyses, and cell and animal models also have limits in reproducing the complex human gland microenvironment.
The authors propose single-cell multi-omics, which jointly analyzes multiple types of molecular information in individual cells; spatial transcriptomics, which maps gene expression within tissue; and gland organoid models as tools for future research. These approaches aim to distinguish macrophage subtypes and their interactions with neighboring cells, and to identify factors that drive a shift into a fibrosis-promoting state.
Technologies for selectively delivering drugs to glands and biomarkers that distinguish macrophage states also remain development priorities. The review states that gland-targeted delivery systems and polarization-specific biomarkers have not yet entered clinical development. This does not mean that clinical procedures have been established for determining prescriptions from biopsy results alone or preventing fibrosis through local administration. The discussion and limitations can be found in the full review and its bibliographic record and abstract.
Sjögren's syndrome (SS) is a chronic systemic autoimmune disease characterized by damage to exocrine glands, and no effective treatment is currently available to reverse glandular fibrosis. As core effector cells of innate immunity, macrophages play a pivotal role in the dynamic imbalance of polarization states, which critically influences inflammation initiation, tissue injury, and irreversible fibrosis in SS. This review systematically delineates the heterogeneity of M1/M2 macrophage subsets, their spatiotemporal dynamics, and their functional transitions across different pathological stages of SS: M1 predominance drives early pro-inflammatory damage, M1/M2 interplay sustains chronic inflammation in the middle stage, and aberrant M2 polarization promotes late-stage glandular fibrosis. We further dissect the multi-level regulatory network underlying macrophage polarization imbalance, including immune cell crosstalk, core signaling pathways, non-coding RNA epigenetic regulation, and immunometabolic reprogramming. The in-depth mechanisms by which M2 macrophages drive the progression of glandular fibrosis are also summarized. In this context, we describe how certain traditional Chinese medicine (TCM) formulas and monomeric compounds can effectively restore the balance of macrophage polarization by targeting relevant pathways and molecular nodes. Moreover, we analyze the major bottlenecks currently hindering the clinical translation of macrophage-targeted strategies and propose innovative approaches, including tissue-specific delivery, spatiotemporally tailored modulation, integrated TCM-western medicine therapy, biomarker-guided patient stratification, and early-window intervention. Finally, we discuss the potential of cutting-edge technologies such as single-cell multi-omics, spatial transcriptomics, gene editing, and organoid models to decode the heterogeneity of macrophage subsets and their interactions with the microenvironment. Integration of these multidisciplinary
This review shows what needs to be distinguished when evaluating strategies that broadly suppress macrophages or shift them toward an M2 state. Their anti-inflammatory and tissue-repair functions must be considered separately from their fibrosis-promoting functions to interpret how candidate compounds act. One possible scenario for follow-up research is to analyze associations among macrophage states, fibrosis severity, and secretory function in human gland tissue, and examine changes following modulation of candidate targets in gland organoids or other models. This approach uses research tools proposed by the review; it is not a validated treatment procedure. Before such findings can inform treatment choices for individual patients, researchers must further establish biomarker predictive performance, the safety of targeted delivery, and actual clinical benefit.